The Experts below are selected from a list of 141 Experts worldwide ranked by ideXlab platform
Ibrahim Batal - One of the best experts on this subject based on the ideXlab platform.
-
membranous nephropathy as a manifestation of graft versus host disease association with HLA Antigen typing phospholipase a2 receptor and c4d
American Journal of Kidney Diseases, 2014Co-Authors: Cathryn J Byrnedugan, Bernard A Collins, Ibrahim BatalAbstract:Glomerulopathy is an uncommon but increasingly recognized complication of hematopoietic cell transplantation. It typically manifests as membranous nephropathy, less commonly as minimal change disease, and rarely as proliferative glomerulonephritis. There is evidence to suggest that these glomerulopathies might represent manifestations of chronic graft-versus-host disease. In this report, we focus on membranous nephropathy as the most common form of glomerulopathy after hematopoietic cell transplantation. We present a case of membranous nephropathy that developed 483 days post–allogeneic hematopoietic stem cell transplantation in a patient with a history of acute graft-versus-host disease. We also share our experience with 4 other cases of membranous nephropathy occurring after allogeneic hematopoietic stem cell transplantation. Clinicopathologic correlates, including the association with graft-versus-host-disease, HLA Antigen typing, glomerular deposition of immunoglobulin G (IgG) subclasses, subepithelial colocalization of IgG deposits with phospholipase A 2 receptor staining, C4d deposition along the peritubular capillaries, and treatment, are discussed with references to the literature.
-
Kidney Biopsy Teaching Case Membranous Nephropathy as a Manifestation of Graft-Versus- Host Disease: Association With HLA Antigen Typing, Phospholipase A2 Receptor, and C4d
2014Co-Authors: Cathryn J. Byrne-dugan, A. Bernard Collins, Ibrahim BatalAbstract:Glomerulopathy is an uncommon but increasingly recognized complication of hematopoietic cell transplantation. It typically manifests as membranous nephropathy, less commonly as minimal change disease, and rarely as proliferative glomerulonephritis. There is evidence to suggest that these glomerulopathies might represent manifestations of chronic graft-versus-host disease. In this report, we focus on membranous nephropathy as the most common form of glomerulopathy after hematopoietic cell transplantation. We present a case of membranous nephropathy that developed 483 days post–allogeneic hematopoietic stem cell transplantation in a patient with a history of acute graft-versus-host disease. We also share our experience with 4 other cases of membranous nephropathy occurring after allogeneic hematopoietic stem cell transplantation. Clinicopathologic correlates, including the association with graft-versus-host-disease, HLA Antigen typing, glomerular deposition of immunoglobulin G (IgG) subclasses, subepithelial colocalization of IgG deposits with phospholipase A2 receptor staining, C4d deposition along the peritubular capillaries, and treatment, are discussed with references to the literature. Am J Kidney Dis. 64(6):987-993. a 2014 by the National Kidney Foundation, Inc.
Andrej F. Bren - One of the best experts on this subject based on the ideXlab platform.
-
Survey of renal transplantation in Slovenia
Therapeutic Apheresis and Dialysis, 2009Co-Authors: Aljoša Kandus, Miha Arnol, Andrej F. BrenAbstract:This brief survey presents data on renal transplantation in Slovenia, a country with a population of 2 million, which has one renal transplant center. The establishment of an appropriate national transplantation organization resulted in an increase in transplantations and the acceptance of Slovenia into Eurotransplant (ET) at the beginning of 2000. Current immunosuppression is composed of cyclosporine microemulsion (Neoral), mycophenolate mofetil, methylprednisolone, and anti-interleukin-2 receptor monoclonal antibodies. By the end of 2008, 766 renal transplantations had been performed, and from 1970 to 2007, 125 patients had been transplanted from living related donors. From 1986 to 1999, 239 patients received renal grafts from deceased donors. From 2000 to 2008, 402 patients were transplanted from deceased donors. In 2004, 55 renal transplantations were done. Two hundred and twenty-eight (56.7%) renal grafts were shipped from other ET countries. The HLA-Antigen mismatch of 2.7 +/- 1.1 was not significantly different to that before 2000. From 2000 to 2008, the one- and five-year patient survival rates were 98.2% and 95.2%, respectively. The concomitant graft survival rates were 94.4% and 90.9%, respectively. In the ET era, the number of deceased donor renal transplants per year was 2.6 times higher than in the 14 years before. In 2004 we reached the average number of deceased donor renal transplants per million population of ET. Short- and medium-term results of the last nine-year period have been very good and entirely comparable to those in large reports.
-
Renal transplantation in Slovenia after joining Eurotransplant
Nephrology Dialysis Transplantation, 2006Co-Authors: Aljoša Kandus, Miha Arnol, Andrej F. BrenAbstract:Background: This report presents data on renal transplantation in Slovenia before and after joining Eurotransplant (ET). Methods: Sloveni a (population: 2 million) has one renal transplant centre. The establishment of an appropriate national transplantation organization resulted in an increase in transplantations and the acceptance of Slovenia into ET at the beginning of 2000. Current immunosuppression is composed of cyclosporin (Neoral®), mycophenolate mofetil, methylprednisolone and anti-interleukin-2 receptor monoclonal antibodies. Results: By the end of 2004, 607 renal transplantations had been performed. From 1970 to 1998, 124 patients were given living related donor kidneys. From 1986 to 1999, 239 patients received renal grafts from deceased donors. From 2000 to 2004, 244 patients were transplanted from deceased donors. In 2004, 55 renal transplantations were carried out. One hundred and forty one (57.8%) renal grafts were shipped from other ET countries. The HLA-Antigen mismatch of 2.8±1.1 was not significantly different from what it was before 2000. Up to 31 December 2004, the 1- and 3-year patient survival rates were 98.3% and 96.0%, respectively. The concomitant graft survival rates were 95.8% and 93.5%, respectively. Conclusions. In the ET era, the number of deceased donor renal transplants per year was 2.8 times higher than in the 14 years before. In 2004, we reached the average number of deceased donor renal transplants per million population of ET. Although tissue compatibility in these recipients was not significantly better than it was before the ET era, it would have been much worse had we not joined ET. Short- and medium-term results in the ET era have been entirely comparable to those in large reports. © The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
W M Linehan - One of the best experts on this subject based on the ideXlab platform.
-
regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation
The New England Journal of Medicine, 2000Co-Authors: Richard Childs, A Chernoff, N Contentin, E Bahceci, David S Schrump, Susan F Leitman, Elizabeth J Read, John F Tisdale, Cynthia E Dunbar, W M LinehanAbstract:Background Since allogeneic stem-cell transplantation can induce curative graft-versus-leukemia reactions in patients with hematologic cancers, we sought to induce analogous graft-versus-tumor effects in patients with metastatic renal-cell carcinoma by means of nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Methods Nineteen consecutive patients with refractory metastatic renal-cell carcinoma who had suitable donors received a preparative regimen of cyclophosphamide and fludarabine, followed by an infusion of a peripheral-blood stem-cell allograft from an HLA-identical sibling or a sibling with a mismatch of a single HLA Antigen. Cyclosporine, used to prevent graft-versus-host disease, was withdrawn early in patients with mixed T-cell chimerism or disease progression. Patients with no response received up to three infusions of donor lymphocytes. Results At the time of the last follow-up, 9 of the 19 patients were alive 287 to 831 days after transplantation (median follow-up, 402 da...
Aljoša Kandus - One of the best experts on this subject based on the ideXlab platform.
-
Survey of renal transplantation in Slovenia
Therapeutic Apheresis and Dialysis, 2009Co-Authors: Aljoša Kandus, Miha Arnol, Andrej F. BrenAbstract:This brief survey presents data on renal transplantation in Slovenia, a country with a population of 2 million, which has one renal transplant center. The establishment of an appropriate national transplantation organization resulted in an increase in transplantations and the acceptance of Slovenia into Eurotransplant (ET) at the beginning of 2000. Current immunosuppression is composed of cyclosporine microemulsion (Neoral), mycophenolate mofetil, methylprednisolone, and anti-interleukin-2 receptor monoclonal antibodies. By the end of 2008, 766 renal transplantations had been performed, and from 1970 to 2007, 125 patients had been transplanted from living related donors. From 1986 to 1999, 239 patients received renal grafts from deceased donors. From 2000 to 2008, 402 patients were transplanted from deceased donors. In 2004, 55 renal transplantations were done. Two hundred and twenty-eight (56.7%) renal grafts were shipped from other ET countries. The HLA-Antigen mismatch of 2.7 +/- 1.1 was not significantly different to that before 2000. From 2000 to 2008, the one- and five-year patient survival rates were 98.2% and 95.2%, respectively. The concomitant graft survival rates were 94.4% and 90.9%, respectively. In the ET era, the number of deceased donor renal transplants per year was 2.6 times higher than in the 14 years before. In 2004 we reached the average number of deceased donor renal transplants per million population of ET. Short- and medium-term results of the last nine-year period have been very good and entirely comparable to those in large reports.
-
Renal transplantation in Slovenia after joining Eurotransplant
Nephrology Dialysis Transplantation, 2006Co-Authors: Aljoša Kandus, Miha Arnol, Andrej F. BrenAbstract:Background: This report presents data on renal transplantation in Slovenia before and after joining Eurotransplant (ET). Methods: Sloveni a (population: 2 million) has one renal transplant centre. The establishment of an appropriate national transplantation organization resulted in an increase in transplantations and the acceptance of Slovenia into ET at the beginning of 2000. Current immunosuppression is composed of cyclosporin (Neoral®), mycophenolate mofetil, methylprednisolone and anti-interleukin-2 receptor monoclonal antibodies. Results: By the end of 2004, 607 renal transplantations had been performed. From 1970 to 1998, 124 patients were given living related donor kidneys. From 1986 to 1999, 239 patients received renal grafts from deceased donors. From 2000 to 2004, 244 patients were transplanted from deceased donors. In 2004, 55 renal transplantations were carried out. One hundred and forty one (57.8%) renal grafts were shipped from other ET countries. The HLA-Antigen mismatch of 2.8±1.1 was not significantly different from what it was before 2000. Up to 31 December 2004, the 1- and 3-year patient survival rates were 98.3% and 96.0%, respectively. The concomitant graft survival rates were 95.8% and 93.5%, respectively. Conclusions. In the ET era, the number of deceased donor renal transplants per year was 2.8 times higher than in the 14 years before. In 2004, we reached the average number of deceased donor renal transplants per million population of ET. Although tissue compatibility in these recipients was not significantly better than it was before the ET era, it would have been much worse had we not joined ET. Short- and medium-term results in the ET era have been entirely comparable to those in large reports. © The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Cathryn J Byrnedugan - One of the best experts on this subject based on the ideXlab platform.
-
membranous nephropathy as a manifestation of graft versus host disease association with HLA Antigen typing phospholipase a2 receptor and c4d
American Journal of Kidney Diseases, 2014Co-Authors: Cathryn J Byrnedugan, Bernard A Collins, Ibrahim BatalAbstract:Glomerulopathy is an uncommon but increasingly recognized complication of hematopoietic cell transplantation. It typically manifests as membranous nephropathy, less commonly as minimal change disease, and rarely as proliferative glomerulonephritis. There is evidence to suggest that these glomerulopathies might represent manifestations of chronic graft-versus-host disease. In this report, we focus on membranous nephropathy as the most common form of glomerulopathy after hematopoietic cell transplantation. We present a case of membranous nephropathy that developed 483 days post–allogeneic hematopoietic stem cell transplantation in a patient with a history of acute graft-versus-host disease. We also share our experience with 4 other cases of membranous nephropathy occurring after allogeneic hematopoietic stem cell transplantation. Clinicopathologic correlates, including the association with graft-versus-host-disease, HLA Antigen typing, glomerular deposition of immunoglobulin G (IgG) subclasses, subepithelial colocalization of IgG deposits with phospholipase A 2 receptor staining, C4d deposition along the peritubular capillaries, and treatment, are discussed with references to the literature.